Income statement, balance sheet and cash flow statement for the last 5 fiscal years, taken from the XBRL data NewAmsterdam Pharma Co N.V. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2021
FY2023
FY2023
FY2024
FY2025
Revenue
103
14.1
45.6
22.5
Research and development
29
86.7
159
151
142
Selling, general and administrative
6
19.5
37.6
70.4
106
General and administrative
13.6
16.3
14.4
15.4
Operating expenses
35
106
197
222
248
Operating income
-35
-3.56
-183
-176
-226
Interest expense
0.41
0.29
Interest income
11.3
16.9
27.6
Pre-tax income
-41.8
-22.6
-177
-242
-204
Income tax
0.03
-0
Net income
-41.8
-22.6
-177
-242
-204
EBITDA
-35
-3.55
-183
-176
-225
EPS, basic
-3.81
-1.19
-2.15
-2.56
-1.72
EPS, diluted
-3.81
-1.19
-2.15
-2.56
-1.72
Shares, basic (weighted)
11
19
82.2
94.4
118
Shares, diluted (weighted)
11
19
82.2
94.4
118
Balance sheet
FY2021
FY2023
FY2023
FY2024
FY2025
Cash and equivalents
468
340
772
490
Short-term investments
62.4
146
Other current assets
10.3
6.34
24.3
38.1
Total current assets
478
347
863
676
Property, plant and equipment
0.03
0.05
0.24
0.38
Lease right-of-use assets
0.12
0.06
0.43
0.19
Long-term investments
92.6
Total assets
478
347
865
769
Accounts payable
11.9
16.9
4.74
8.97
Deferred revenue
13.9
8.94
6.01
3.99
Total current liabilities
36.1
49.9
107
85.8
Lease liabilities
0.06
0.2
0.07
Total liabilities
48.4
58.7
107
85.9
Paid-in capital
556
591
1,298
1,427
Retained earnings
-140
-317
-559
-762
Other comprehensive income
4.42
4.42
4.47
4.79
Shareholders' equity
-114
430
288
758
683
Total equity
-114
430
288
758
683
Total liabilities and equity
478
347
865
769
Shares outstanding
81.6
82.5
108
114
Cash flow statement
FY2021
FY2023
FY2023
FY2024
FY2025
Net income
-41.8
-22.6
-177
-242
-204
Depreciation and amortization
0.01
0.01
0.05
0.11
0.22
Stock-based compensation
1.24
4.12
24.6
33.6
59.4
Change in payables
6.56
4.81
5.07
-12.9
4.91
Cash from operations
-29.5
10.7
-141
-159
-148
Capital expenditures
-0.02
-0.22
-0.02
-0.67
-0.25
Purchases of investments
-62.2
-297
Sales and maturities of investments
122
Cash from investing
-0.02
-0.22
-0.02
-62.8
-175
Stock issued
0.29
1.77
29.5
Cash from financing
84.7
392
8.91
660
29.5
Net change in cash
55.2
402
-132
438
-293
Free cash flow
-29.5
10.4
-141
-159
-148
Interest paid
0.28
Income taxes paid
0.03
0
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $22.58 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Operating margin
-3,432.0%
Operating income / revenue.
EBITDA margin
-3,427.0%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
-3,644.0%
Pre-tax income / revenue.
Net margin
-3,644.0%
Net income / revenue.
FCF margin
-2,018.0%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-2,015.0%
Cash from operations / revenue.
Return on equity (ROE)
-41.1%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-36.8%
Net income / average total assets.
Return on invested capital (ROIC)
-93.2%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue
2,096.0%
Research and development expense / revenue.
SG&A / revenue
1,436.0%
Selling, general and administrative expense / revenue.
Stock-based pay / revenue
918.6%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
3.7%
Capital expenditures / revenue.
D&A / revenue
4.7%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
-50.6%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
-39.7%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value growth, 1y
-9.8%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
16.7%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets growth, 1y
-11.0%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
17.1%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Share count change, 1y
25.5%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
84.1%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
9.03x
Current assets / current liabilities.
Quick ratio
8.69x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
8.69x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.06
Revenue / diluted weighted shares.
FCF per share
-$1.16
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$1.16
Cash from operations / diluted weighted shares.
Book value per share
$5.37
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
379x
Market cap / revenue.
P/B
4.27x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
4.27x
Market cap / tangible book value, when positive.
EV/Sales
290x
Enterprise value / revenue.
FCF yield
-5.3%
Free cash flow / market cap.
Earnings yield
-9.6%
Net income / market cap (the inverse of P/E).
What was NewAmsterdam Pharma Co N.V.'s revenue in fiscal 2025?
NewAmsterdam Pharma Co N.V. reported revenue of $22.5M for fiscal 2025, 50.6% lower than the year before.
Was NewAmsterdam Pharma Co N.V. profitable in fiscal 2025?
No. It reported a net loss of $203.8M.
How much free cash flow did NewAmsterdam Pharma Co N.V. generate in fiscal 2025?
Cash from operations of $147.8M minus capital expenditures of $246.0K left free cash flow of -$148.0M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.